Odense Universitetshospital
- Address
- Kløvervænget 19, Odense, Denmark
Odense Universitetshospital - Gynecologic Oncology Research
Odense Universitetshospital is actively engaged in cutting-edge clinical research focused on advancing treatment strategies for gynecologic malignancies. The center demonstrates particular expertise in investigating novel therapeutic combinations for recurrent ovarian cancer, with emphasis on precision medicine approaches targeting specific patient populations.
- Maintenance therapy strategies in BRCA wild-type ovarian cancer patients
- Combination immunotherapy approaches using checkpoint inhibitors and cancer vaccines
- PARP inhibitor-based treatment regimens for gynecologic cancers
The center's research portfolio includes innovative trials examining the synergistic potential of olaparib, durvalumab, and UV1 vaccination as maintenance treatment options. This multifaceted approach reflects the institution's commitment to developing personalized treatment strategies that may improve outcomes for patients with recurrent ovarian cancer, particularly those without BRCA mutations who have historically had limited targeted therapy options.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Odense Universitetshospital
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Olaparib, Durvalumab, and UV1 as Maintenance Therapy in BRCA Wild-Type Recurrent Ovarian Cancer: A Randomized Clinical Trial | Nordic Society Of Gynaecological Oncology Clinical Trial Unit | Phase II | Not Recruiting | Nov 2024 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alrefimotide | 1 | Unknown | 2024-11-13 | 2024-11-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.